PMID- 23192460
OWN - NLM
STAT- MEDLINE
DCOM- 20130812
LR  - 20220801
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
VI  - 172
IP  - 3
DP  - 2013 Mar
TI  - Maculopapular rash in the convalescent phase of Kawasaki disease: case series and 
      literature review.
PG  - 405-7
LID - 10.1007/s00431-012-1898-y [doi]
AB  - Intravenous immunoglobulin (IVIG) is currently the standard treatment for 
      Kawasaki disease (KD). Although IVIG therapy is generally well tolerated, several 
      minor adverse reactions have been reported. We report a patient with KD treated 
      with IVIG, who developed a cutaneous reaction in the convalescent phase 
      (approximately 10 days after therapy). We identified seven additional KD cases 
      with a similar presentation, accounting for 9.3 % of KD patients at our hospital. 
      We performed a literature review and found that a maculopapular rash could be 
      observed approximately 10 days after IVIG treatment, in patients with and those 
      without KD. CONCLUSION: Maculopapular rash can occur in nearly 10 % of 
      IVIG-treated children with KD in our cohort, approximately 10 days after 
      treatment. A delayed-onset adverse event of IVIG could be a causative etiology of 
      this unrecognized eruption.
FAU - Takeuchi, Masato
AU  - Takeuchi M
AD  - Department of Pediatrics, Chigasaki Municipal Hospital, Honson 5-15-1, Chigasaki, 
      Kanagawa, Japan. masatotakeuchi@gmail.com
FAU - Oda, Yoichiro
AU  - Oda Y
FAU - Suzuki, Isao
AU  - Suzuki I
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20121129
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Child, Preschool
MH  - Convalescence
MH  - Drug Eruptions/*diagnosis/etiology
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/therapeutic use
MH  - Immunologic Factors/*adverse effects/therapeutic use
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
EDAT- 2012/11/30 06:00
MHDA- 2013/08/13 06:00
CRDT- 2012/11/30 06:00
PHST- 2012/08/23 00:00 [received]
PHST- 2012/11/15 00:00 [accepted]
PHST- 2012/11/14 00:00 [revised]
PHST- 2012/11/30 06:00 [entrez]
PHST- 2012/11/30 06:00 [pubmed]
PHST- 2013/08/13 06:00 [medline]
AID - 10.1007/s00431-012-1898-y [doi]
PST - ppublish
SO  - Eur J Pediatr. 2013 Mar;172(3):405-7. doi: 10.1007/s00431-012-1898-y. Epub 2012 
      Nov 29.